Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.

Salih HR, Nuessler V, Denzlinger C, Starling GC, Kiener PA, Schmetzer HM.

Leuk Lymphoma. 2004 Feb;45(2):301-8.

PMID:
15101715
2.

Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.

Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, Schmetzer HM.

Eur J Haematol. 2006 Aug;77(2):91-101. Epub 2006 Jun 23.

PMID:
16800841
3.

Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.

Hirano T, Hiratsuka N, Iwahori T, Oka K, Wakasugi K.

Res Commun Mol Pathol Pharmacol. 2003;113-114:315-28.

PMID:
15686130
4.

Expression of CD137 and CD137 ligand in colorectal cancer patients.

Dimberg J, Hugander A, Wågsäter D.

Oncol Rep. 2006 May;15(5):1197-200.

PMID:
16596186
5.

Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD.

Claessens YE, Park S, Dubart-Kupperschmitt A, Mariot V, Garrido C, Chrétien S, Dreyfus F, Lacombe C, Mayeux P, Fontenay M.

Blood. 2005 May 15;105(10):4035-42. Epub 2005 Jan 27.

6.

Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.

Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K, Chayama K.

Oncol Rep. 2004 Jun;11(6):1183-6.

PMID:
15138553
7.

What does apoptosis have to do with clinical features in myelodysplastic syndrome?

Ramos F, Fuertes-Núñez M, Suárez-Vilela D, Fernández-López A.

Haematologica. 2002 Apr;87(4):381-91.

8.
9.

Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.

Lundberg LG, Hellström-Lindberg E, Kanter-Lewensohn L, Lerner R, Palmblad J.

Leuk Res. 2006 Mar;30(3):247-53. Epub 2005 Aug 15.

PMID:
16099505
10.

The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance.

Alexandrakis MG, Passam FH, Dambaki K, Passam AM, Nalbanti F, Stathopoulos ES, Kyriakou DS.

Eur J Histochem. 2005 Jan-Mar;49(1):27-32.

PMID:
15823791
11.

Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.

Gianelli U, Fracchiolla NS, Cortelezzi A, Pellegrini C, Savi F, Moro A, Grimoldi MG, Deliliers GL, Coggi G, Bosari S.

Ann Hematol. 2007 Mar;86(3):185-9. Epub 2006 Nov 24.

PMID:
17124585
12.

Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.

Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A.

Eur J Haematol. 2008 Feb;80(2):107-14. Epub 2007 Nov 17.

PMID:
18028430
13.
14.
15.

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF.

Blood. 2007 Jun 1;109(11):4816-24. Epub 2007 Mar 6.

16.

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ.

Blood. 2008 Feb 1;111(3):1067-77. Epub 2007 Oct 30.

17.

Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes.

Wang XQ, Chen ZX, Chen SC, Lin GW, Ji MR, Liang JY, Liu DD, Li DG, Ma Y.

Chin Med J (Engl). 2008 Sep 20;121(18):1787-91.

PMID:
19080358
18.

Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.

Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T.

Cancer. 2004 Oct 15;101(8):1794-802.

19.
20.

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J.

J Am Coll Cardiol. 2005 Apr 5;45(7):1018-24.

Supplemental Content

Support Center